Loading...
•
Jun 30, 2021
Zevra Q2 2021 Earnings Report
Reported revenue of $12.0 million driven by milestone payment and service fees, with a net income of $0.18 per basic share.
Key Takeaways
KemPharm reported a strong second quarter with a revenue of $12.0 million and a net income of $6.2 million, driven by a $10 million milestone payment for DEA scheduling of SDX and $2.0 million in service fee revenue. The company also saw significant progress with the commercial launch of AZSTARYS and the classification of SDX as a Schedule IV controlled substance.
Initiated U.S. Commercial Launch of AZSTARYS™ on July 21, 2021.
Serdexmethylphenidate (SDX) Classified as a Schedule IV Controlled Substance by the DEA.
Confirmed receipt of $10 million milestone payment for DEA scheduling of SDX.
Total cash and cash equivalents was $132.3 million at June 30, 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...